Elsevier

Neuropharmacology

Volume 57, Issue 3, September 2009, Pages 259-267
Neuropharmacology

Characterizing the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice

https://doi.org/10.1016/j.neuropharm.2009.05.011Get rights and content

Abstract

5-HT2C receptor agonists have considerable therapeutic potential, however there is little in vivo data to compare the potency and selectivity of 5-HT2C receptor agonists. Since 5-HT2C receptor agonists reduce locomotor activity and food intake, changes in these drug-induced behaviours in 5-HT2C receptor knockout mice could provide a means to examine receptor selectivity in-vivo. Initially this study compared older 5-HT2C agonists mCPP and MK212, to newer, apparently more selective compounds: Ro 60-0175, WAY161503, CP809,101 and lorcaserin (APD356) on motor activity in wild-type, and 5-HT2C receptor knockout mice. Two 5-HT2C receptor antagonists SB242084 and SDZ SER 082 were also examined. mCPP did not significantly alter activity in wild-type mice, but enhanced activity in knockout animals. MK212 (3 and 10 mg/kg) and Ro 60-0175 (1 and 3 mg/kg) reduced activity in wild-type but not knockout animals. At 10 mg/kg, Ro 60-0175 reduced activity in knockout animals, suggesting loss of 5-HT2C receptor selectivity. CP809,101 and lorcaserin reduced activity in wild-type but not knockout mice. In subsequent feeding studies, Ro 60-0175 and lorcaserin reduced food intake in wild-type animals only. Selectivity of effect for mCPP was marginal. The antagonist SB242084 increased activity in wild-type animals but not in knockout mice; SB242084 did not alter feeding in either genotype. SDZ SER 082 reduced activity in both genotypes implying poor selectivity for 5-HT2C receptors. The data demonstrate that studying food intake, and particularly motor behaviour, in the 5-HT2C receptor knockout mouse is a useful and relatively simple approach for screening 5-HT2C receptor ligands in vivo.

Introduction

The 5-HT2 receptor family comprises the 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes, each sharing approximately 46–50% sequence homology (Barnes and Sharp, 1999, Hoyer et al., 2002). Various agonists for these receptors have been identified. Early examples of 5-HT2C receptor agonists include the piperazine analogs mCPP (Curzon and Kennett, 1990) and MK-212 (Clineschmidt et al., 1977). However, these compounds, particularly mCPP, have negligible selectivity for the 5-HT2C receptor over other 5-HT subtypes (e.g. Hamik and Peroutka, 1989, Porter et al., 1999), requiring antagonist studies to fully interpret receptor activity. Two 5-HT2C receptor antagonists are SDZ SER 082 (Nozulak et al., 1995) and SB242084 (Bromidge et al, 1997; Kennett et al., 1997). Next, Ro 60-0175 emerged as a 5-HT2C agonist, albeit with significant agonist property at the 5-HT2B receptor (Martin et al., 1998, Porter et al., 1999). Nonetheless, as with mCPP and MK-212 a significant body of data derived partly from studies with 5-HT2C receptor antagonists supports the value of this compound as a 5-HT2C receptor agonist (e.g. Clifton et al., 2000, Higgins and Fletcher, 2003).

Driven by the therapeutic potential of 5-HT2C receptor agonists, newer compounds have been developed including WAY161503 (Rosenzweig-Lipson et al., 2006), lorcaserin (APD356) (Smith et al., 2005, Thomsen et al., 2008) and CP809,101 (Siuciak et al., 2007). Pharmacological data suggest that these compounds, compared to mCPP, MK212 and Ro 60-0175, have greater selectivity for the 5-HT2C receptor (see Table 1), which is important given the adverse properties associated with activation of 5-HT2A and 5-HT2B receptor subtypes (Barnes and Sharp, 1999, Rothman et al., 2000). Preclinical studies with these drugs suggest that selective 5-HT2C receptor agonists have anti-psychotic, anti-depressant and anti-obesity potential (Cryan and Lucki, 2000, Jones and Blackburn, 2002, Nilsson, 2006, Siuciak et al., 2007), and are effective in reducing drug self-administration and reinstatement (Higgins and Fletcher, 2003, Bubar and Cunningham, 2008).

The 5-HT2C receptor knockout mouse provides a further tool to explore the function of this receptor subtype (Tecott et al., 1995), including a means for determining drug specificity at this target. In wild-type animals mCPP reduces locomotor activity, but in 5-HT2C receptor knockout mice mCPP paradoxically elicits hyperactivity. Subsequent pharmacological studies have shown that this effect results from 5-HT1B/2A receptor activation by mCPP (Heisler and Tecott, 2000, Dalton et al., 2004). Thus, removal of the 5-HT2C receptor results in the unmasking, or expression, of additional pharmacological properties of mCPP.

The present studies examined the effects of a number of 5-HT2C receptor agonists (mCPP, Ro 60-0175, MK212, lorcaserin, CP809,101 and WAY161503) on motor activity in 5-HT2C receptor knockout mice to determine their in vivo functional selectivity for the 5-HT2C receptor. The effects of dexfenfluramine were also examined because many of its in vivo effects appear to be mediated via 5-HT2C receptors, despite the fact that it is a general 5-HT releaser (Fuller et al., 1988). For example, the anorectic effect of dexfenfluramine is attenuated in 5-HT2C receptor knockout mice (Vickers et al., 1999). In addition, because there are occasional reports suggesting that 5-HT2C receptor antagonists increase locomotion (Martin et al., 2002), we included SB242084 and SDZ SER 082 in these studies. Based on the results of these studies we selected several ligands to compare the profile of effects on locomotor activity with their effects on food intake in a palatability-induced feeding test. These drugs were the 5-HT2C receptor agonists mCPP, Ro 60-0175 and lorcaserin and the 5-HT2C receptor antagonist SB242084. The feeding study with lorcaserin is of particular interest because this drug is presently in a Phase 3 obesity trial, having successfully demonstrated efficacy in a 12 week Phase 2 trial (Smith et al., 2009).

Section snippets

Animals and housing

Adult 5-HT2C knockout and wild-type mice (8–12 weeks of age at the beginning of experiments) were used. For all studies involving knockout mice animals were obtained from our in-house breeding colony. Mice were group housed, with ad libitum access to food and water under a 12 h light/dark cycle (lights on at 8 am). For one pharmacological study examining the interaction between SDZ SER 082 and Ro 60-0175 male C57BL/6 mice were purchased from Charles River (St. Constant, Quebec). The 5-HT2C

Comparison of basal motor activity counts, and food intake, following vehicle treatment in wild-type and 5-HT2C receptor knockout mice

Basal activity counts between experiments for wild-type mice injected with saline appeared to vary across experiments. A one-way analysis of variance was used to analyse these counts across the various experiments. This confirmed a significant main effect of group (F8,56 = 3.26, p < 0.001). A Bonferroni test, to allow for all possible group mean comparisons, showed that only the MK212 and SB242084 groups were significantly different from each other. Indeed, following a one-way analysis of

Discussion

There is a considerable body of experimental data describing hypolocomotor effects of various 5-HT2C receptor agonists in rodents. Such effects have been described for mCPP in rats and mice (Kennett and Curzon, 1988a, Kennett and Curzon, 1988b, Lucki et al., 1989, Gleason et al., 2001), MK-212 (Lucki et al., 1989), Ro 60-0175 (Kennett et al., 2000, Higgins et al., 2001), WAY161503 (Mosher et al., 2005), and CP809,101 (Siuciak et al., 2007) in rats. 5-HT2C receptors are localized on inhibitory

Acknowledgements

This work was supported in part by an operating grant from the Canadian Institutes of Health Research to PJF. Some of these data were presented at the 37th Annual Meeting, Society for Neuroscience, San Diego, CA. November 2007.

References (53)

  • A. Hamik et al.

    1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain

    Biol. Psychiatry

    (1989)
  • K.N. Hewitt et al.

    Serotonin 2C receptor agonists and the behavioural satiety sequence in mice

    Pharmacol. Biochem. Behav.

    (2002)
  • G.A. Higgins et al.

    Serotonin and drug reward: focus on 5-HT2C receptors

    Eur. J. Pharmacol.

    (2003)
  • D. Hoyer et al.

    Molecular, pharmacological and functional diversity of 5-HT receptors

    Pharmacol. Biochem. Behav.

    (2002)
  • B.J. Jones et al.

    The medical benefits of 5-HT research

    Pharmacol. Biochem. Behav.

    (2002)
  • G.A. Kennett et al.

    Effects of RO 60-0175, a 5-HT2C receptor agonist, in three animal models of anxiety

    Eur. J. Pharmacol.

    (2000)
  • G.A. Kennett et al.

    SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist

    Neuropharmacology

    (1997)
  • M.J. Millan et al.

    5-HT2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in-vivo.

    Neuropharmacology

    (1998)
  • T. Mosher et al.

    Differential effects of 5-HT2C receptor ligands on place conditioning and locomotor activity in rats

    Eur. J. Pharmacol.

    (2005)
  • S. Rosenzweig-Lipson et al.

    Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503

    Brain Res.

    (2006)
  • J.A. Siuciak et al.

    CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

    Neuropharmacology

    (2007)
  • B.M. Smith et al.

    Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity

    Bioorg. Med. Chem. Lett.

    (2005)
  • S.M. Bromidge et al.

    6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist

    J. Med. Chem.

    (1997)
  • C.M. Burns et al.

    Regulation of serotonin-2C receptor G-protein coupling by RNA editing

    Nature

    (1997)
  • P.G. Clifton et al.

    Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat

    Psychopharmacology (Berl)

    (2000)
  • B.V. Clineschmidt et al.

    Anorexigenic and ancillary actions of MK-212 (6-chloro-2-(1-piperazinyl)-pyrazine; CPP)

    Psychopharmacology

    (1977)
  • Cited by (0)

    1

    Current addresses: CanCog Technologies, 120 Carlton Street, Toronto, Ontario M5A 4K2, Canada.

    2

    Current addresses: Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St., Suite 800, Toronto, Ontario M5G OA3, Canada.

    3

    Current addresses: Fluorinov Pharmaceuticals, 4780 Fulwell Road, Mississauga, Ontario L5M 7J7, Canada.

    View full text